Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

ABSTRACT:

Background

Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). Treatment guidelines propose dose escalation based on clinical assessments of disease response.

Methods

Response and survival were analyzed in a cohort of patients (n = 106) with newly diagnosed CML-CP who were enrolled on the International Randomized Study of Interferon and STI571 (IRIS) trial, who began treatment with imatinib at a dose of 400 mg daily, and who subsequently underwent dose escalation to either 600 mg or 800 mg daily. Reasons for dose escalation were evaluated retrospectively based on 2 sets of criteria: the IRIS protocol-defined criteria (n = 39 patients) and the European L

SUBMITTER: Kantarjian HM 

PROVIDER: S-EPMC4445370 | biostudies-literature | 2009 Feb

REPOSITORIES: biostudies-literature